Hospital Cardioversion Program (IV Fixed Dose Combination)

About InCarda Therapeutics

InCarda Therapeutics is a private, pre-revenue biotech company founded in 2009 and headquartered in San Francisco, with operational offices in Utah and Australia. The company is advancing a pipeline of inhaled therapies for the acute treatment of paroxysmal atrial fibrillation (AF) and atrial flutter (AFL), with programs targeting both medically supervised hospital use and patient self-administration at home. Led by a team with deep expertise in cardiology and drug development, InCarda aims to transform AFib management by offering a faster, more patient-centric alternative to current intravenous or oral systemic therapies.

Therapeutic Areas